Genetic Technologies announces the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test. Highlights: Pancreatic cancer has a very high mortality rate, approximately 76%1 of those diagnosed will die within 1 year. The five-year survival rate is only 9%. GeneType’s Pancreatic Cancer risk assessment test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer. GeneType for Pancreatic Cancer will lead to a significant improvement to the number of pancreatic cancers being discovered earlier. When identified early, surgical intervention can save lives. The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank, identifying 851 incident cases of pancreatic cancer, providing a very powerful validation of the geneType model. Identifying those at-risk will enable doctors and their patients to increase surveillance and be proactive in their efforts to prevent the development of cancer. GTG’s Chief Commercial Officer, Carl Stubbings said, “Around 65,000 people will be diagnosed with pancreatic in the U.S. this year and 50,000 people will die3. This devastating statistic is driven by late diagnosis of this cancer. Implementing geneType risk assessment test for pancreatic cancer will help doctors diagnose the disease earlier, intervene earlier and reduce this appalling mortality. This test really can make a difference in improving patient outcomes.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GENE:
- GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment
- GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
- Genetic Technologies signs precision medicine pilot with GCPH
- GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner
- Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV
